Literature DB >> 14532773

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.

Anthony L Zietman1, Dianne Sacco, Uri Skowronski, Pablo Gomery, Donald S Kaufman, Jack A Clark, James A Talcott, William U Shipley.   

Abstract

PURPOSE: Transurethral resection, chemotherapy and radiation with salvage cystectomy may be used as alternatives to immediate radical cystectomy in the management of invasive bladder cancer. Concern exists about the function of the retained bladder after such therapy.
MATERIALS AND METHODS: Of 221 patients with clinical T2-4a bladder cancer treated at Massachusetts General Hospital from 1986 to 2000 with trimodality therapy, 71 were alive with native bladders and disease-free in 2001. These patients were asked to undergo a urodynamic study and to complete a quality of life questionnaire. A total of 69% participated in some component of this study with a median time from trimodality therapy of 6.3 years (range 1.6 to 14.9).
RESULTS: Of 32 patients 24 had normally functioning bladders by urodynamic study. Decreased bladder compliance was seen in 7. Bladder hypersensitivity, involuntary detrusor contractions and incontinence were present in 2 women. The questionnaire showed that flow symptoms occurred in 6%, urgency in 15% and control problems in 19%. Of all women 11% wore pads. Distress from urinary symptoms was half as common as prevalence. Bowel symptoms occurred in 22% with 14% recording any level of distress. The majority of men retained sexual function. Global health related quality of life was high.
CONCLUSIONS: The majority of patients treated with trimodality therapy retain good bladder function. A fifth have evidence of bowel dysfunction.

Entities:  

Mesh:

Year:  2003        PMID: 14532773     DOI: 10.1097/01.ju.0000093721.23249.c3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  48 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 3.  Current management of muscle-invasive bladder cancer.

Authors:  G Sancho; P Maroto; J Palou
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

Review 4.  Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Kirk A Keegan; Matthew J Resnick; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

5.  Gender, age and surgery as a treatment modality leads to higher distress in patients with cancer.

Authors:  Bejoy C Thomas; V NandaMohan; Madhvan K Nair; Manoj Pandey
Journal:  Support Care Cancer       Date:  2010-02-23       Impact factor: 3.603

6.  Surgery: selective bladder-preserving therapy for muscle-invasive cancer.

Authors:  Niall M Heney; Donald S Kaufman; William U Shipley
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 7.  Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Skyler B Johnson; James B Yu
Journal:  Curr Oncol Rep       Date:  2018-06-30       Impact factor: 5.075

8.  Bladder cancer: Quality of life in patients with non-muscle-invasive bladder cancer.

Authors:  Alejandro Sanchez; Matthew F Wszolek
Journal:  Nat Rev Urol       Date:  2015-02-03       Impact factor: 14.432

9.  In favour of bladder preservation using combined modality treatment.

Authors:  Himu Lukka
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

Review 10.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.